Business Context and Reporting Period
Company: Passage BIO, Inc. (PASG)
Filing Type: Form 8-K (Current Report)
Date: September 16, 2024
Context: The filing discloses updated interim safety and biomarker data from the Company's ongoing global Phase 1/2 clinical trial, upliFT-D, evaluating PBFT02, a gene therapy for frontotemporal dementia caused by progranulin deficiency (FTD-GRN). The report also references a poster presentation at the 14th International Conference on Frontotemporal Dementias (ISFTD2024).
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial updates and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Updates
The filing details significant clinical progress for the PBFT02 program in Cohort 1 patients receiving Dose 1:
- Safety: PBFT02 was well-tolerated in all patients (n=4) who received an enhanced immunosuppression regimen following a protocol amendment, as of August 20, 2024.
- Biomarker Efficacy (CSF PGRN):
- Progranulin (PGRN) levels in cerebral spinal fluid (CSF) increased in all patients relative to baseline.
- One Month: Up to a 6-fold increase (range: 10.7 to 17.3 ng/mL; n=5).
- Six Months: Up to a 10-fold increase (range: 21.7 to 27.3 ng/mL; n=2).
- Twelve Months: Levels remained elevated in one patient, reaching 34.2 ng/mL.
- Comparison to Controls: CSF PGRN levels exceeded the range found in healthy adult controls (3.3 to 8.2 ng/mL).
- Rate of Increase: The rate of increase was 58% between one and six months, slowing to 26% between six and twelve months.
- Plasma Levels: Plasma PGRN expression remained below healthy reference levels across all patients.
Guidance, Outlook, and Risks
Management Commentary: The data suggests consistent effects across patients with sustained elevation of PGRN in the CSF. The filing includes a press release and corporate presentation as exhibits.
Risks and Contingencies: The filing explicitly states that the information in Item 7.01 and accompanying exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings, except as expressly set forth. No specific financial risks or forward-looking guidance regarding revenue or timelines were included in this specific text.
Investor Verification Checklist
- Verify the full text of the attached press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2) for additional context on the clinical trial design.
- Review the ISFTD2024 Poster (Exhibit 99.3) for detailed statistical analysis of the biomarker data.
- Confirm the status of the enhanced immunosuppression regimen and its long-term safety profile in future reports.
- Monitor upcoming filings for financial updates, as this 8-K contains no financial data.